RecruitingPhase 2NCT07437586

Topical GHK-Cu Gel for Acute Skin Wound Healing

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu (Copper(II)-Peptide Complex) Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults

Sponsor

Hudson Biotech

Enrollment

60 participants

Start Date

Feb 2, 2026

Study Type

INTERVENTIONAL

Conditions

Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)

Summary

This study will evaluate whether a topical gel containing GHK-Cu (a copper(II)-peptide complex) can safely speed up healing of small, standardized skin wounds in healthy adults compared with a matching vehicle gel. Participants will receive two small punch-biopsy wounds on the upper arm; each wound will be randomly assigned to receive GHK-Cu gel or vehicle gel under identical dressings. Wounds will be photographed and assessed over 3 weeks, with a follow-up visit to evaluate scar quality.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GHK-Cu Gel (Copper(II)-peptide complex) and a drug called vehicle Gel (placebo comparator) for people with acute standardized cutaneous wounds (punch-biopsy wounds). The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGHK-Cu Gel (Copper(II)-peptide complex)

topical gel, 0.1% w/w; apply a thin film (approx. 0.5 g) once daily for 14 days.

DRUGvehicle Gel (placebo comparator)

ehicle Gel (placebo comparator

Locations(1)

Peking University Shenzhen Hospital

Shenzhen, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07437586